PeptideSearch

ARA-290

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-05-14

Also called Cibinetide / Erythropoietin-derived peptide

Derived from the hormone EPO but without its blood effects. Tested in people for nerve pain.

Official status: 503A Category 3 – nominated without adequate support · Checked 2026-05-14

Can a doctor prescribe this?

Small pharmacy (503A)
Category 3 — not enough evidence sent in
Large outsourcing facility (503B)
Never put forward to FDA

Investigational, and not approved. The FDA has "Cibinetide (ARA-290)" in Category 3 of the substances put forward for small-pharmacy (503A) compounding: what was sent in did not include enough evidence for the FDA to judge it.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 8

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 14 May 2026503A

    FDA lists "Cibinetide (ARA-290)" under 503A Category 3: Bulk Drug Substances Nominated Without Adequate Support. Read from the FDA 503A category document headed "Updated May 14, 2026".

    FDA

We'll email you when a new study, trial or status change lands for ARA-290. Unsubscribe in one click.